Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 285 publications

Semaglutide (Wegovy) for MASH.

Semaglutide (Wegovy) for MASH.

Journal: The Medical letter on drugs and therapeutics
Published: October 08, 2025

Metabolic dysfunction-associated steatohepatitis treatment: spotlight on the latest hepatoprotective drugs.

Metabolic dysfunction-associated steatohepatitis treatment: spotlight on the latest hepatoprotective drugs.

Journal: Expert opinion on pharmacotherapy
Published: September 24, 2025

Therapeutic advances in metabolic dysfunction-associated steatotic liver disease

Therapeutic advances in metabolic dysfunction-associated steatotic liver disease

Journal: Revue medicale suisse
Published: September 10, 2025

Corrected T1 (cT1) is the most appropriate diagnosis and monitoring tool for widespread adoption of resmetirom treatment in the United States.

Corrected T1 (cT1) is the most appropriate diagnosis and monitoring tool for widespread adoption of resmetirom treatment in the United States.

Journal: Journal of medical economics
Published: August 27, 2025

New Names, New Drugs, Better Outcomes in Steatotic Liver Disease.

New Names, New Drugs, Better Outcomes in Steatotic Liver Disease.

Journal: British journal of hospital medicine (London, England : 2005)
Published: August 23, 2025

MASLD Pharmacotherapy: Current Standards, Emerging Treatments, and Practical Guidance for Indian Physicians.

MASLD Pharmacotherapy: Current Standards, Emerging Treatments, and Practical Guidance for Indian Physicians.

Journal: The Journal of the Association of Physicians of India
Published: August 21, 2025

Translating Trial to Treatment: A Scoping Review of Resmetirom First Year in Real-World Use for Moderate to Advanced Fibrosis in Metabolic Dysfunction-Associated Steatohepatitis.

Translating Trial to Treatment: A Scoping Review of Resmetirom First Year in Real-World Use for Moderate to Advanced Fibrosis in Metabolic Dysfunction-Associated Steatohepatitis.

Journal: Cureus
Published: August 16, 2025

Pathogenesis and Treatment of Non-alcoholic Steatohepatitis and Its Fibrosis: A Systematic Review.

Pathogenesis and Treatment of Non-alcoholic Steatohepatitis and Its Fibrosis: A Systematic Review.

Journal: Cureus
Published: August 10, 2025

Resmetirom and thyroid hormone receptor-targeted treatment for metabolic dysfunction-associated steatotic liver disease (MASLD).

Resmetirom and thyroid hormone receptor-targeted treatment for metabolic dysfunction-associated steatotic liver disease (MASLD).

Journal: Portal hypertension & cirrhosis
Published: August 08, 2025

Discovery of Highly Potent, Selective, and Liver-Targeted THR-β Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.

Discovery of Highly Potent, Selective, and Liver-Targeted THR-β Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.

Journal: Journal of medicinal chemistry
Published: August 05, 2025

Resmetirom for MASH: A Comprehensive Review of a Novel Therapeutic Frontier.

Resmetirom for MASH: A Comprehensive Review of a Novel Therapeutic Frontier.

Journal: Biomedicines
Published: July 27, 2025

Development of a cross-species model to predict clinical outcomes based on efficacy in mouse models of non-alcoholic fatty liver disease.

Development of a cross-species model to predict clinical outcomes based on efficacy in mouse models of non-alcoholic fatty liver disease.

Journal: Clinics and research in hepatology and gastroenterology
Published: July 24, 2025
Showing 1-12 of 285

Last Updated: 10/31/2025